Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing-Reference-Cited by-全球学者库

Assessing and advancing the safety of CRISPR-Cas tools: from DNA to RNA editing

Published:2023-01-13 Issue:1 Volume:14 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Tao Jianli^ORCID,Bauer Daniel E.,Chiarle Roberto^ORCID

Abstract

AbstractCRISPR-Cas gene editing has revolutionized experimental molecular biology over the past decade and holds great promise for the treatment of human genetic diseases. Here we review the development of CRISPR-Cas9/Cas12/Cas13 nucleases, DNA base editors, prime editors, and RNA base editors, focusing on the assessment and improvement of their editing precision and safety, pushing the limit of editing specificity and efficiency. We summarize the capabilities and limitations of each CRISPR tool from DNA editing to RNA editing, and highlight the opportunities for future improvements and applications in basic research, as well as the therapeutic and clinical considerations for their use in patients.

Funder

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary

Link

https://www.nature.com/articles/s41467-023-35886-6.pdf

Reference247 articles.

1. Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229–236 (2020).

2. Raguram, A., Banskota, S. & Liu, D. R. Therapeutic in vivo delivery of gene editing agents. Cell https://doi.org/10.1016/j.cell.2022.03.045 (2022).

3. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012). This paper reported the very first use of SpCas9 nuclease and single-guide RNAs (developed from dual-tracrRNA:crRNA) for programmable DNA cutting.